Metformin for Central Centrifugal Cicatricial Alopecia: Emerging Antifibrotic Evidence and Mechanistic Insights

This article explores the emerging antifibrotic properties of metformin, particularly its potential in treating Central Centrifugal Cicatricial Alopecia (CCCA). While metformin is primarily used for managing type 2 diabetes, recent studies suggest its ability to modulate fibrosis through AMPK activation, offering a potential therapeutic approach for CCCA. This review examines the current evidence and the mechanistic insights into metformin's role in modifying the fibrotic processes in CCCA.